FINCH THERAPEUTICS
Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts.
FINCH THERAPEUTICS
Industry:
Biotechnology Clinical Trials Machine Learning Therapeutics
Founded:
2017-01-01
Address:
Somerville, Massachusetts, United States
Country:
United States
Website Url:
http://www.finchtherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(617) 229-6499
Total Funding:
188.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Board_member
Current Employees Featured
Zain Kassam Co-Founder & Chief Medical Officer @ Finch Therapeutics
Co-Founder & Chief Medical Officer
2019-09-01
Greg Perry CFO @ Finch Therapeutics
CFO
2018-05-01
Andrew Noh Chief Operating Officer @ Finch Therapeutics
Chief Operating Officer
2019-06-01
James Burgess Co-Founder and VP of Innovation @ Finch Therapeutics
Co-Founder and VP of Innovation
2014-11-01
Michelle Hylan Clinical Consultant @ Finch Therapeutics
Clinical Consultant
2020-08-01
Joseph Vittiglio Chief Business & Legal Officer @ Finch Therapeutics
Chief Business & Legal Officer
2021-01-01
James Burgess VP Innovation & Co-Founder @ Finch Therapeutics
VP Innovation & Co-Founder
2017-01-01
Mark Smith CEO @ Finch Therapeutics
CEO
2016-08-01
Gregory D. Perry Chief Financial Officer @ Finch Therapeutics
Chief Financial Officer
2018-05-01
Marc B. Blaustein Chief Operating Officer @ Finch Therapeutics
Chief Operating Officer
2021-09-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-10-23 | Crestovo | Crestovo acquired by Finch Therapeutics | N/A |
Investors List
Symbiosis Group
Symbiosis Group investment in Series D - Finch Therapeutics
Willett Advisors LLC
Willett Advisors LLC investment in Series D - Finch Therapeutics
MSD Capital
MSD Capital investment in Series D - Finch Therapeutics
Octave Group
Octave Group investment in Series D - Finch Therapeutics
Susquehanna International Group (SIG)
Susquehanna International Group (SIG) investment in Series D - Finch Therapeutics
OMX Ventures
OMX Ventures investment in Series D - Finch Therapeutics
Octave Ventures LLC
Octave Ventures LLC investment in Series D - Finch Therapeutics
MSD Partners
MSD Partners investment in Series D - Finch Therapeutics
Avenir Growth Capital
Avenir Growth Capital investment in Series D - Finch Therapeutics
Humboldt Fund
Humboldt Fund investment in Series D - Finch Therapeutics
Key Employee Changes
Official Site Inspections
http://www.finchtherapeutics.com Semrush global rank: 225.66 K Semrush visits lastest month: 322.22 K
- Host name: 104.21.3.217
- IP address: 104.21.3.217
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Finch Therapeutics"
About - Finch Therapeutics
About us Our board of directors Key milestones in the field & Finch’s history 4th century First written accounts emerge from China of therapeutic applications of microbial therapies. 1958 Ben Eiseman et al. publishes first report of four …See details»
Finch Therapeutics Group Company Description - Stock Analysis
3 days ago Company profile for Finch Therapeutics Group, Inc. (FNCH) with a description, list of executives, contact details and other key facts.See details»
Finch Therapeutics - Crunchbase Company Profile
Contact Email info@finchtherapeutics.com Phone Number (617) 229-6499 Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical …See details»
Finch Therapeutics Group Inc (FNCH) Profile - The Globe and Mail
See the company profile for Finch Therapeutics Group Inc (FNCH) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Finch Therapeutics Group - Overview, News & Similar ... - ZoomInfo
May 10, 2023 Finch Announces Reverse Stock Split of Common Stock BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the …See details»
Working At Finch Therapeutics: Company Overview and Culture
Mar 14, 2024 www.finchtherapeutics.com. Organization Type. Public. Social Media. Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel …See details»
Investor Relations — Finch Therapeutics
Apr 25, 2023 Corporate profile. Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with …See details»
Portfolio — Finch Therapeutics
About our portfolio of microbiome assets The microbiome: Essential for health.Harnessed for medicine. The microbiome consists of trillions of microbes that live symbiotically in and on …See details»
Finch Therapeutics Group (FNCH) Stock Price, News & Analysis
6 days ago www.finchtherapeutics.com. Phone 617-229-6499. Fax N/A. Employees 190. Year Founded N/A. Profitability. EPS (Most Recent Fiscal Year) ($8.82) Trailing P/E Ratio N/A. …See details»
Finch Therapeutics (USA) Funding: $188.8M - Medical Startups
Nov 23, 2024 Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut...See details»
Finch Therapeutics - LinkedIn
Finch Therapeutics | 9,549 followers on LinkedIn. Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered …See details»
Finch Therapeutics - Craft
Finch Therapeutics is a biotech company that develops novel microbiome therapeutics. Its products include FIN-211, a microbiome designed to address the gastrointestinal and …See details»
Finch Therapeutics to Participate in Upcoming June Investor …
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics …See details»
Finch Therapeutics Group, Inc. (FNCH) Stock Price, News, Quote ...
Find the latest Finch Therapeutics Group, Inc. (FNCH) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Finch Therapeutics Group Raises $36 Million in Series B Financing
Mar 1, 2018 Financing to support ongoing Phase 2 study of CP101 in recurrent C. difficile infection and advance pipeline of earlier stage products. SOMERVILLE, Mass.–(BUSINESS …See details»
Finch Therapeutics Provides Business Update - GlobeNewswire
Sep 1, 2022 Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & …See details»
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 …
Aug 25, 2022 About FIN-524 & FIN-525 for Inflammatory Bowel Disease. FIN-524 and FIN-525 are investigational, orally administered targeted consortia product candidates composed of …See details»
Finch Therapeutics Announces $90 Million Financing to Advance …
Sep 17, 2020 Investor Contact: Greg Perry ir@finchtherapeutics.com. Release Summary. Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral …See details»
Finch Therapeutics Reports First Quarter 2021 Financial Results …
May 13, 2021 ir@finchtherapeutics.com . Finch Therapeutics Group, Inc. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per …See details»
Two gene therapies for sickle cell approved by FDA | AP News
Dec 8, 2023 The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, …See details»